These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients. Amaral MD J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997 [TBL] [Abstract][Full Text] [Related]
23. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473 [TBL] [Abstract][Full Text] [Related]
24. [Azithromycin therapy in cystic fibrosis]. Máiz Carro L; Cantón Moreno R Med Clin (Barc); 2004 Mar; 122(8):311-6. PubMed ID: 15030744 [TBL] [Abstract][Full Text] [Related]
25. Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Torphy TJ; Allen J; Cantin AM; Konstan MW; Accurso FJ; Joseloff E; Ratjen FA; Chmiel JF; Ann Am Thorac Soc; 2015 Sep; 12(9):1398-406. PubMed ID: 26146892 [TBL] [Abstract][Full Text] [Related]
26. Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery. Davies JC; Drevinek P; Elborn JS; Kerem E; Lee T; ; Amaral MD; de Boeck K; Davies JC; Drevinek P; Elborn JS; Kerem E; Lee T J Cyst Fibros; 2019 Sep; 18(5):677-684. PubMed ID: 31303382 [TBL] [Abstract][Full Text] [Related]
27. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis. Tay GT; Reid DW; Bell SC Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593 [TBL] [Abstract][Full Text] [Related]
28. State of progress in treating cystic fibrosis respiratory disease. Flume PA; Van Devanter DR BMC Med; 2012 Aug; 10():88. PubMed ID: 22883684 [TBL] [Abstract][Full Text] [Related]
29. Drug development for cystic fibrosis. Sanders DB; Chmiel JF Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S10-S22. PubMed ID: 32940969 [TBL] [Abstract][Full Text] [Related]
30. Adherence to therapies in cystic fibrosis: a targeted literature review. Narayanan S; Mainz JG; Gala S; Tabori H; Grossoehme D Expert Rev Respir Med; 2017 Feb; 11(2):129-145. PubMed ID: 28107795 [TBL] [Abstract][Full Text] [Related]
31. Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages. Gillan JL; Davidson DJ; Gray RD Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303535 [TBL] [Abstract][Full Text] [Related]
35. Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand? Klinger-Strobel M; Lautenschläger C; Fischer D; Mainz JG; Bruns T; Tuchscherr L; Pletz MW; Makarewicz O Expert Opin Drug Deliv; 2015 Aug; 12(8):1351-74. PubMed ID: 25642831 [TBL] [Abstract][Full Text] [Related]